Antifibrotic, Antioxidant, and Immunomodulatory Effects of Mesenchymal Stem Cells in HOCl-Induced Systemic Sclerosis

Arthritis and Rheumatology

Volumn 68, Issue 4, 2016, Pages 1013-1025

  Maria, Alexandre T J ^a   Toupet, Karine ^a   Bony, Claire ^a   Pirot, Nelly ^b   Vozenin, Marie Catherine ^c   Petit, Benoît ^c   Roger, Pascal ^a,d   Batteux, Frédéric ^e   Le Quellec, Alain ^a   Jorgensen, Christian ^a   Noël, Danièle ^a   Guilpain, Philippe ^a  

^a UNIV MONTPELLIER   (France)

^b University of Montpellier   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d DEPARTMENT OF NEUROLOGY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AUTOANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 3; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ACTA2 PROTEIN, MOUSE; ACTIN; DNA TOPOISOMERASE; HYPOCHLOROUS ACID; OXIDIZING AGENT; TGFB1 PROTEIN, MOUSE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; AUTOIMMUNITY; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; EXTRACELLULAR MATRIX; HISTOLOGY; IMMUNOMODULATION; LUNG FIBROSIS; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; MYOFIBROBLAST; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROSIS; SKINFOLD; SKINFOLD THICKNESS; SYSTEMIC SCLEROSIS; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; GENETICS; IMMUNOLOGY; LUNG; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PULMONARY FIBROSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCLERODERMA, DIFFUSE; SKIN;

ACTINS; ANIMALS; AUTOANTIBODIES; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; DNA TOPOISOMERASES, TYPE I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROSIS; HYPOCHLOROUS ACID; LUNG; MESENCHYMAL STEM CELL TRANSPLANTATION; MICE; OXIDANTS; OXIDATIVE STRESS; PULMONARY FIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, DIFFUSE; SKIN; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84962045240     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39477     Document Type: Article

References (50)

1. Walker KM, Pope J, participating members of the Scleroderma Clinical Trials Consortium (SCTC), Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55.
2. Van Laar JM, Sullivan K., Stem cell transplantation in systemic sclerosis. Curr Opin Rheumatol 2013; 25: 719-25.
3. Cipriani P, Carubbi F, Liakouli V, Marrelli A, Perricone C, Perricone R, et al., Stem cells in autoimmune diseases: implications for pathogenesis and future trends in therapy. Autoimmun Rev 2013; 12: 709-16.
4. Maumus M, Guerit D, Toupet K, Jorgensen C, Noel D., Mesenchymal stem cell-based therapies in regenerative medicine: applications in rheumatology. Stem Cell Res Ther 2011; 2: 14.
5. Zhou H, Guo M, Bian C, Sun Z, Yang Z, Zeng Y, et al., Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report. Biol Blood Marrow Transplant 2010; 16: 403-12.
6. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al., Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11: 150-6.
7. Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, et al., Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther 2014; 16: R79.
8. De la Portilla F, Alba F, Garcia-Olmo D, Herrerias JM, Gonzalez FX, Galindo A., Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013; 28: 313-23.
9. Guiducci S, Porta F, Saccardi R, Guidi S, Ibba-Manneschi L, Manetti M, et al., Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report. Ann Intern Med 2010; 153: 650-4.
10. Keyszer G, Christopeit M, Fick S, Schendel M, Taute BM, Behre G, et al., Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases. Arthritis Rheum 2011; 63: 2540-2.
11. Inamdar AC, Inamdar AA., Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp Lung Res 2013; 39: 315-27.
12. Batteux F, Kavian N, Servettaz A., New insights on chemically induced animal models of systemic sclerosis. Curr Opin Rheumatol 2011; 23: 511-8.
13. Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al., Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 2009; 182: 5855-64.
14. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D., IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PloS One 2010; 5: e14247.
15. Toupet K, Maumus M, Peyrafitte JA, Bourin P, van Lent PL, Ferreira R, et al., Long-term detection of human adipose-derived mesenchymal stem cells after intraarticular injection in SCID mice. Arthritis Rheum 2013; 65: 1786-94.
16. Servettaz A, Guilpain P, Goulvestre C, Chereau C, Hercend C, Nicco C, et al., Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007; 66: 1202-9.
17. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, et al., Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100: 8407-11.
18. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, et al., Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33: 145-52.
19. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al., Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci U S A 2007; 104: 11002-7.
20. Zhao F, Zhang YF, Liu YG, Zhou JJ, Li ZK, Wu CG, et al., Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 2008; 40: 1700-5.
21. Cargnoni A, Gibelli L, Tosini A, Signoroni PB, Nassuato C, Arienti D, et al., Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant 2009; 18: 405-22.
22. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al., Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009; 175: 303-13.
23. Kubo M, Ihn H, Yamane K, Tamaki K., Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731-4.
24. Vanneaux V, Farge-Bancel D, Lecourt S, Baraut J, Cras A, Jean-Louis F, et al., Expression of transforming growth factor β receptor II in mesenchymal stem cells from systemic sclerosis patients. BMJ Open 2013; 3: e001890.
25. Denton CP, Zheng B, Evans LA, Shi-wen X, Ong VH, Fisher I, et al., Fibroblast-specific expression of a kinase-deficient type II transforming growth factor β (TGFβ) receptor leads to paradoxical activation of TGFβ signaling pathways with fibrosis in transgenic mice. J Biol Chemistry 2003; 278: 25109-19.
26. Hashemi SM, Ghods S, Kolodgie FD, Parcham-Azad K, Keane M, Hamamdzic D, et al., A placebo controlled, dose-ranging, safety study of allogenic mesenchymal stem cells injected by endomyocardial delivery after an acute myocardial infarction. Eur Heart J 2008; 29: 251-9.
27. Desando G, Cavallo C, Sartoni F, Martini L, Parrilli A, Veronesi F, et al., Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. Arthritis Res Ther 2013; 15: R22.
28. Murphy MB, Moncivais K, Caplan AI., Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013; 45: e54.
29. Wolf D, Reinhard A, Seckinger A, Katus HA, Kuecherer H, Hansen A., Dose-dependent effects of intravenous allogeneic mesenchymal stem cells in the infarcted porcine heart. Stem Cells Dev 2009; 18: 321-9.
30. Joo SY, Cho KA, Jung YJ, Kim HS, Park SY, Choi YB, et al., Mesenchymal stromal cells inhibit graft-versus-host disease of mice in a dose-dependent manner. Cytotherapy 2010; 12: 361-70.
31. Von Bahr L, Batsis I, Moll G, Hagg M, Szakos A, Sundberg B, et al., Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. Stem Cells 2012; 30: 1575-8.
32. Ankrum JA, Ong JF, Karp JM., Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32: 252-60.
33. Maumus M, Jorgensen C, Noel D., Mesenchymal stem cells in regenerative medicine applied to rheumatic diseases: role of secretome and exosomes. Biochimie 2013; 95: 2229-34.
34. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C., Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 2009; 5: 392-9.
35. Conese M, Carbone A, Castellani S, Di Gioia S., Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases. Cells Tissues Organs 2013; 197: 445-73.
36. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al., Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
37. Garantziotis S, Brass DM, Savov J, Hollingsworth JW, McElvania-TeKippe E, Berman K, et al., Leukocyte-derived IL-10 reduces subepithelial fibrosis associated with chronically inhaled endotoxin. Am J Respir Cell Mol Biol 2006; 35: 662-7.
38. Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K., In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-β in the lung. Thorax 2006; 61: 886-94.
39. Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, et al., Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem 2002; 277: 35466-74.
40. Spight D, Zhao B, Haas M, Wert S, Denenberg A, Shanley TP., Immunoregulatory effects of regulated, lung-targeted expression of IL-10 in vivo. Am J Physiol Lung Cell Mol Physiol 2005; 288: L251-65.
41. Sun L, Louie MC, Vannella KM, Wilke CA, LeVine AM, Moore BB, et al., New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol 2011; 300: L341-53.
42. Frost J, Ramsay M, Mia R, Moosa L, Musenge E, Tikly M., Differential gene expression of MMP-1, TIMP-1 and HGF in clinically involved and uninvolved skin in South Africans with SSc. Rheumatology (Oxford) 2012; 51: 1049-52.
43. Khokha R, Murthy A, Weiss A., Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013; 13: 649-65.
44. Cipriani P, Di Benedetto P, Capece D, Zazzeroni F, Liakouli V, Ruscitti P, et al., Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. Fibrogenesis Tissue Repair 2014; 7: 13.
45. Kavian N, Servettaz A, Marut W, Nicco C, Chereau C, Weill B, et al., Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis Rheum 2012; 64: 1990-2000.
46. Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al., Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18: 759-65.
47. Lee C, Mitsialis SA, Aslam M, Vitali SH, Vergadi E, Konstantinou G, et al., Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012; 126: 2601-11.
48. Cho KA, Woo SY, Seoh JY, Han HS, Ryu KH., Mesenchymal stem cells restore CCl4-induced liver injury by an antioxidative process. Cell Biol Int 2012; 36: 1267-74.
49. Marangoni RG, Korman BD, Wei J, Wood TA, Graham LV, Whitfield ML, et al., Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors. Arthritis Rheumatol 2015; 67: 1062-73.
50. Liu S, Herault Y, Pavlovic G, Leask A., Skin progenitor cells contribute to bleomycin-induced skin fibrosis. Arthritis Rheumatol 2014; 66: 707-13.